EDMONTON, June 29 /PRNewswire-FirstCall/ - Isotechnika Inc. announced today that the Company will be represented at the 81st Annual Conference of the Canadian Dermatology Association. Dr. Richard Langley, one of the principal investigator’s involved in the Company’s Phase III psoriasis trial will make an oral presentation at 10:45 a.m. ET/9:45 a.m. CT on July 1st at the Fort Garry Hotel in Winnipeg, Manitoba.
The following posters will also be on display during the conference: ‘Pharmacokinetics and Pharmacodynamics of ISA247 in a Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled Study’ and ‘A Phase III, Randomized, Multicentre, Double-Blind, Placebo-Controlled, Quality of Life Study of ISA247 in Plaque Psoriasis.’ Both posters will be on display from June 29-30, 2006, and presented on behalf of Isotechnika Inc.
All interested parties are encouraged to view Dr. Langley’s presentation and the posters on our corporate Web site at www.isotechnika.com in the Investor Relations section.
About Isotechnika -----------------
Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.
Isotechnika’s lead compound, ISA247 is an immunosuppressant currently in an extension protocol of a Canadian Phase III human clinical trial for the treatment of moderate to severe psoriasis and a North American Phase IIb human clinical trial for the prevention of kidney graft rejection. The Company also has an additional immunosuppressive compound in its drug pipeline, TAFA93 which is in Phase I.
Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol ISA. More information on Isotechnika can be found at www.isotechnika.com.
Partnerships ------------
In May, 2006, Isotechnika signed an exclusive worldwide agreement to license its lead drug, ISA247 for ophthalmic indications with Lux Biosciences Inc.
Isotechnika signed an Option Agreement in April, 2006, with Cellgate to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate’s patented transporter technology for the topical delivery of ISA247 in patients suffering from mild to moderate psoriasis.
An exclusive worldwide licensing agreement was signed in September, 2005, with Atrium Medical Corporation for the use of ISA247 and TAFA93 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular, target vessel and tissue disorders.
Isotechnika Inc. also has a collaboration agreement with Hoffman La Roche which licensed the worldwide rights to develop and commercialize Isotechnika’s novel molecule ISA247 for all transplant indications.
Forward-Looking Statements
--------------------------
This press release may contain forward-looking statements. Forward looking statements, including the Company’s belief as to the potential of its products, the Company’s expectations regarding the issuance of additional patents and the Company’s ability to protect its intellectual property, involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the ability to economically manufacture its products, the potential of its products, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize its products, the ability of the Company to defend its patents from infringement by third parties, and the risk that the Company’s patents may be subsequently shown to be invalid or infringe the patents of others. Investors should consult the Company’s quarterly and annual filings with the Canadian commissions for additional information on risks and uncertainties relating to the forward- looking statements. Investors are cautioned against placing undue reliance on forward-looking statements.
Isotechnika Inc.
CONTACT: Stephanie Gillis-Paulgaard, Director, Corporate Communications,Isotechnika Inc., (780) 909-4661, (780) 484-4105 (fax),sgillis-paulgaard@isotechnika.com; Archived images on this organization aresearchable through CNW Photo Archive website at http://photos.newswire.ca.Images are free to accredited members of the media. To request a free copyof this organization’s annual report, please go to http://www.newswire.caand click on Tools for Investors.
